TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15173128

Group type: EXPERIMENTAL
Intervention: Low sodium intake (sodium restriction)
Number of subjects: 12
Study: 12117291

Group type: EXPERIMENTAL
Intervention: Heparin rinse at 2,000 IU/L
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heparin rinse at 10,000 IU/L
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Saline rinse
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy individuals (comparison group)
Number of subjects: 11
Study: 9647354

Group type: EXPERIMENTAL
Intervention: Skin mini-erosion sampling technique
Number of subjects: 13
Study: 8077904

Group type: EXPERIMENTAL
Intervention: Distal paracervical block
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intramucosal block
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both blocks
Number of subjects: 77
Study: 2555894

Group type: EXPERIMENTAL
Intervention: Polygynax
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 1114210

Group type: EXPERIMENTAL
Intervention: Supportive preoperative interview (long and relatively informative with maximal rapport)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cursory preoperative interview (brief and minimally informative)
Number of subjects: 40
Study: 30898822

Group type: COMPARATOR
Intervention: Belimumab SC 200 mg/week for 52 weeks plus placebo at weeks 4 and 6
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Belimumab SC 200 mg/week for 52 weeks plus rituximab 1000 mg at weeks 4 and 6
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Belimumab SC 200 mg/week plus standard of care for 104 weeks
Number of subjects: 200
Study: 28319456

Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 198

Group type: COMPARATOR
Intervention: Gardasil®
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 198
Study: 25477424

Group type: EXPERIMENTAL
Intervention: 200 mg 6R‐BH4 twice daily + 1 mg folic acid once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo + folic acid
Number of subjects: 36
Study: 24147622

Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg/kg/day, titrated to 5-10 mg/kg/day based on serum ferritin trends)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Deferasirox (mean actual dose 33.6 mg/kg/day in 1-year extension)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 117

Group type: COMPARATOR
Intervention: Deferasirox (compared to non-Chinese patients)
Number of subjects: 117
Study: 21879641

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Individual cognitive-behavioral therapy
Number of subjects: 22
Study: 19517675

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia (group B, n=27, 0.5% hyperbaric bupivacaine, 1.2 mL + 0.1 mL per every 10 cm over 170 cm height)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bilateral spinal anaesthesia (group K, n=27, 0.5% bupivacaine 2.4 mL + 0.2 mL per every 10 cm over 170 cm height)
Number of subjects: 54
Study: 16997310

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 81
Study: 15564907

Group type: EXPERIMENTAL
Intervention: Directional exercises matching their preferred direction (DP)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Exercises directionally opposite their DP
Number of subjects: 312

Group type: COMPARATOR
Intervention: Nondirectional exercises
Number of subjects: 312
Study: 11287776

Group type: EXPERIMENTAL
Intervention: Pyridoxine 50 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 36
Study: 9148879

Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7999470

Group type: EXPERIMENTAL
Intervention: Screening mammography restricted to women with risk factors for breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual screening prescriptions based on risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: General screening for all women younger than 50
Number of subjects: 0
Study: 31906801

Group type: EXPERIMENTAL
Intervention: Balance Training (BT) conducted over five weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CON) receiving regular physical education lessons
Number of subjects: 72
Study: 30085175

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 240
Study: 27564856

Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion (ACDF) plus physiotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 59
Study: 26523993

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg daily for 104 weeks
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 24131167

Group type: EXPERIMENTAL
Intervention: Nicotine patch + nicotine nasal spray
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nicotine patch + placebo nasal spray
Number of subjects: 22
Study: 21112774

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with cisplatin (100mg/m(2) for three cycles) plus adjuvant cisplatin (80 mg/m(2)) and fluorouracil (1000 mg/m(2)/day for 4 days for three cycles)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Cisplatin during concurrent phase
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Fluorouracil during adjuvant phase
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Concurrent cycles of cisplatin
Number of subjects: 441
Study: 18438106

Group type: EXPERIMENTAL
Intervention: Normal food at will from the first day after surgery
Number of subjects: 453

Group type: COMPARATOR
Intervention: Nil‐by‐mouth and enteral tube feeding (ETF group)
Number of subjects: 453
Study: 16180033

Group type: EXPERIMENTAL
Intervention: (99m)Tc-ECD/123I-FP-CIT SPECT in IPD patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: (99m)Tc-ECD/123I-FP-CIT SPECT in MSA patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 19
Study: 12657406

Group type: EXPERIMENTAL
Intervention: Aprotinin (1,000,000 KIU loading dose, followed by an infusion of 250,000 KIU/hr)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo infusion (normal saline)
Number of subjects: 63
Study: 10755072

Group type: EXPERIMENTAL
Intervention: Unpublished rating scales
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gold-standard definition of treatment superiority with unpublished scales
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Non-pharmacological trials with unpublished scales
Number of subjects: 300
Study: 9014667

Group type: EXPERIMENTAL
Intervention: Conventional carbon dioxide pneumoperitoneum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abdominal wall lift method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 1313717

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg o.d.
Number of subjects: 487

Group type: COMPARATOR
Intervention: Griseofulvin 500 mg o.d.
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Number of subjects: 487

Group type: COMPARATOR
Intervention: Griseofulvin 500 mg ultramicronized daily for 15 days (tinea corporis/cruris) and 30 days (tinea pedis/manus).
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily.
Number of subjects: 487

Group type: COMPARATOR
Intervention: Griseofulvin 500 mg daily.
Number of subjects: 487
Study: 3902268

Group type: EXPERIMENTAL
Intervention: Flurbiprofen + adriamycin + vinca alkaloid
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Adriamycin + vindesine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Adriamycin + vincristine
Number of subjects: 183

Group type: COMPARATOR
Intervention: Adriamycin + vinca alkaloid
Number of subjects: 183
Study: 31307095

Group type: EXPERIMENTAL
Intervention: Diced cartilage with I‐PRF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diced cartilage without I‐PRF (control group)
Number of subjects: 40
Study: 29607554

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate ointment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate ointment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hydrocortisone ointment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vehicles
Number of subjects: 76
Study: 26088405

Group type: EXPERIMENTAL
Intervention: High-dose dimethylfumarate (DMF)
Number of subjects: 176
Study: 25232107

Group type: EXPERIMENTAL
Intervention: Serotonin modulation through pharmaceutical intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral evidence
Number of subjects: 0
Study: 23364034

Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 114

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 114
Study: 20195284

Group type: EXPERIMENTAL
Intervention: Multiple activity-low TV cluster (women)
Number of subjects: 4682

Group type: EXPERIMENTAL
Intervention: Endurance physical activity-low TV cluster (women)
Number of subjects: 4682

Group type: EXPERIMENTAL
Intervention: Endurance physical activity cluster (men)
Number of subjects: 4682

Group type: COMPARATOR
Intervention: Referent cluster (walking and gardening-low TV for men; walking and gardening-high TV for women)
Number of subjects: 4682
Study: 17093981

Group type: EXPERIMENTAL
Intervention: Atomoxetine (max 1.8 mg/kg/day, daily) for 6-8 weeks
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 512
Study: 16303728

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control
Number of subjects: 143
Study: 12145241

Group type: EXPERIMENTAL
Intervention: NN2211 (1.25, 2.5, 5.0, 10.0, 12.5, 15.0, 17.5, and 20.0 microg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 9631204

Group type: EXPERIMENTAL
Intervention: Agnew Relationship Measure (ARM) completed by clients after every session (N = 1120)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Agnew Relationship Measure (ARM) completed by therapists after every session (N = 1120)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Client initiative scale from the ARM
Number of subjects: 95
Study: 8576747

Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin administration (boluses every 8 minutes)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Continuous oxytocin administration (conventional continuous intravenous infusion)
Number of subjects: 38
Study: 2131793

Group type: EXPERIMENTAL
Intervention: VMCP (vincristine, melphalan, cyclophosphamide, and prednisone)
Number of subjects: 614

Group type: COMPARATOR
Intervention: HBI (sequential hemibody radiation with vincristine and prednisone)
Number of subjects: 614
Study: 773486

Group type: EXPERIMENTAL
Intervention: guanethidine and oxprenolol combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 13
Study: 30312788

Group type: EXPERIMENTAL
Intervention: Polyp sizing poster intervention for 33 endoscopists
Number of subjects: 38307

Group type: COMPARATOR
Intervention: Control group for 29 endoscopists
Number of subjects: 38307
Study: 28657141

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26341358

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation intervention for 3 months, exercise 5 days a week using an iPad-based system, weekly video-conferencing with tele-therapists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 24257410

Group type: EXPERIMENTAL
Intervention: Self-help app based on acceptance and commitment therapy and mindfulness-based cognitive behavioural therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-help app
Number of subjects: 150
Study: 21788542

Group type: EXPERIMENTAL
Intervention: Cranberry capsules, 500 mg twice daily
Number of subjects: 221

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX), 480 mg once daily
Number of subjects: 221
Study: 19105776

Group type: EXPERIMENTAL
Intervention: Variall cementless hip system
Number of subjects: 333

Group type: COMPARATOR
Intervention: Conventional polyethylene bearing
Number of subjects: 333
Study: 16849391

Group type: EXPERIMENTAL
Intervention: Internet-delivered HIV risk-reduction intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 90
Study: 12639647

Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (FMS) using the Pulsegen device, B = 10 microT intensity, frequency of 10 Hz, worn day and night for 2 months.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo group (no active treatment).
Number of subjects: 55
Study: 10831274

Group type: EXPERIMENTAL
Intervention: UFT (400 mg/day) administered orally for 7 days prior to surgery
Number of subjects: 96
Study: 9386863

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/sqm day 1; fluorouracil 370 mg/sqm and L-folinic acid 100 mg/sqm days 1-3 administered every three weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prolonged 5FU/L-FA schedule (5 days)
Number of subjects: 46
Study: 8465871

Group type: EXPERIMENTAL
Intervention: Imipramine or phenelzine
Number of subjects: 0
Study: 3001519

Group type: EXPERIMENTAL
Intervention: Intranasal alpha 2-interferon (5 X 10(6) IU)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 30742482

Group type: EXPERIMENTAL
Intervention: Social support from spouse/partner or children
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Interventions to promote ART adherence
Number of subjects: 319
Study: 28130435

Group type: EXPERIMENTAL
Intervention: GnRH-antagonist protocol
Number of subjects: 1050

Group type: COMPARATOR
Intervention: GnRH-agonist protocol
Number of subjects: 1050
Study: 27842526

Group type: EXPERIMENTAL
Intervention: Randomized controlled intervention trial for pediatric weight management (EPOC study)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Completers of the intervention
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Families with a more structured eating environment
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analyses
Number of subjects: 523
Study: 25016303

Group type: EXPERIMENTAL
Intervention: WHELD intervention (comprehensive staff training on person-centred care, activities, and psychotropic medication use)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 22743313

Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nut-free diet (NFD)
Number of subjects: 123
Study: 19618831

Group type: EXPERIMENTAL
Intervention: Lidocaine without infusion (Group IV)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lidocaine without infusion and restart infusion before propofol (Group VI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Saline without infusion (Group III)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 360
Study: 17888016

Group type: EXPERIMENTAL
Intervention: Implant-supported single-tooth replacements with different augmentation procedures
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patient satisfaction questionnaire
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Correlation between professional and patient ratings
Number of subjects: 93
Study: 15727387

Group type: EXPERIMENTAL
Intervention: Home phototherapy (Bluelite Portable Light)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hospital phototherapy (intense phototherapy with top and bottom light sources)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hospital phototherapy
Number of subjects: 36
Study: 11816479

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR plus cisplatin
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5'‐DFUR alone
Number of subjects: 42
Study: 10223775

Group type: EXPERIMENTAL
Intervention: Test product (200 mg carbamazepine tablet 3 times a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference product (200 mg carbamazepine tablet 3 times a day)
Number of subjects: 32
Study: 8574859

Group type: EXPERIMENTAL
Intervention: Microwaved spinach (150 g, 4.3 g dietary fibre)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microwaved spinach (250 g, 7.2 g dietary fibre)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control meal without spinach
Number of subjects: 10
Study: 2239886

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid plus ursodeoxycholic acid (5 mm/kg of each)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (10 mm/kg) alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 120
Study: 721788

Group type: EXPERIMENTAL
Intervention: Prazepam in divided doses
Number of subjects: 847

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study: 31302494

Group type: EXPERIMENTAL
Intervention: Normal pressure lumbosacral orthosis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High pressure lumbosacral orthosis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no orthosis)
Number of subjects: 48
Study: 27757733

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg for 1 week, then 50 mg for 3 weeks, then eplerenone 50 mg for 1 month)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg for 1 week, then 50 mg for 3 weeks, then spironolactone 50 mg for 1 month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1 tablet for 1 week, then 2 tablets for 3 weeks, then spironolactone 50 mg for 1 month)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spironolactone and Eplerenone (both groups 1 and 2)
Number of subjects: 60
Study: 26000578

Group type: EXPERIMENTAL
Intervention: Neutropenic diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-neutropenic diet
Number of subjects: 46
Study: 23890774

Group type: EXPERIMENTAL
Intervention: Positive Action (PA) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study: 20737243

Group type: EXPERIMENTAL
Intervention: 8 mg Cu/day (copper sulfate) for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Copper challenge with 1, 5, and 20 μM Cu-histidine for 20 hours
Number of subjects: 0
Study: 18548559

Group type: EXPERIMENTAL
Intervention: BSS-based technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regression analysis
Number of subjects: 20
Study: 17691886

Group type: EXPERIMENTAL
Intervention: Combination cessation medications
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Behavioral counseling and combination pharmacotherapy
Number of subjects: 470
Study: 14872400

Group type: EXPERIMENTAL
Intervention: Simulation of bilateral movement training through mirror reflection
Number of subjects: 0
Study: 11710825

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha2a, interleukin‐2, and 5‐fluorouracil
Number of subjects: 78

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 78
Study: 9385973

Group type: EXPERIMENTAL
Intervention: Textured implants
Number of subjects: 25

Group type: COMPARATOR
Intervention: Smooth implants
Number of subjects: 25
Study: 7964949

Group type: EXPERIMENTAL
Intervention: vindesine-cisplatin (VP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: best supportive care
Number of subjects: 0
Study: 6690630

Group type: EXPERIMENTAL
Intervention: N‐methyl‐2‐pyrrolidone (NMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimethylformamide (DMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2‐pyrrolidone (2‐P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1‐ethyl‐2‐pyrrolidone (EP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propylene glycol (PG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N,N‐diethyl‐m‐toluamide (DEET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DMI (dimethylisosorbide)
Number of subjects: 0
Study: 31257613

Group type: COMPARATOR
Intervention: Camelina sativa oil (CSO) providing 10 g/day alpha-linolenic acid (ALA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Fatty fish (four fish meals/week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lean fish (four fish meals/week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control diet with limited fish and ALA containing oil consumption
Number of subjects: 79
Study: 29273470

Group type: EXPERIMENTAL
Intervention: IsaGenesis soft gel formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Product B powdered capsule
Number of subjects: 12
Study: 26854478

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) for 16 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Collaborative Assessment and Management of Suicidality (CAMS) for up to 16 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 108
Study: 24219314

Group type: EXPERIMENTAL
Intervention: Verbal n-back task training (10 or 20 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0